In later life, weight loss can be a double‑edged sword. A few pounds off the joints can be both helpful and risky. Shedding a few pounds may ease joint pain, but losing weight without meaning to can be a warning sign. Fast weight loss can also lead to muscle loss, which is key to staying independent.

Experts also point out practical issues: injections need good vision, steady hands, and a regular routine. Stomach and bowel side effects can be tougher for seniors, especially if they’re already losing weight without trying. complicate life for older adults — and how to approach them with a “safety first” mindset.

1) Aging changes the risk–benefit math (even when a drug “works”)

Older adults, especially those who are frail or have several health issues, are often left out of clinical trials. This is important because average trial results may not match the real-life experience of a 75-year-old who takes several medications and needs to manage appetite and hydration.

A 2024 debate paper on GLP-1 drugs in older patients, including those with kidney disease, points out that limited trial data and multiple medications make it harder to judge safety and effectiveness for frailer seniors. Clinicians need to make decisions based on each person, not just on averages. In simple terms, the real question is not whether GLP-1s are good or bad, but whether they help this specific older person with their unique health needs.

There’s another subtle issue: in later life, the goal is often less about chasing an ideal weight and more about protecting function—walking safely, rising from a chair, maintaining balance, staying hydrated, and maintaining enough strength to live independently. So for older adults, the most important question isn’t “How much weight will I lose?” It’s “What will this do to my strength, my nutrition, and my ability to stay steady on my feet?”

2) Common side effects can become serious for older adults.

GLP-1s often cause nausea, vomiting, diarrhea, constipation, and less appetite. Younger people may find these symptoms unpleasant but manageable. For older adults, though, these issues can quickly lead to dehydration, dizziness, and falls, especially if they also take blood pressure medicines or diuretics.

Current FDA labeling for semaglutide products highlights this pathway: stomach and bowel side effects can lead to volume depletion, and acute kidney injury has occurred, including in postmarketing reports. The label advises monitoring kidney function when starting or increasing doses in people who develop severe gastrointestinal reactions, and it notes that dehydration has been part of reported kidney injury cases.

This is how many real-life problems start: a few days of not being able to eat or drink much, then feeling lightheaded, falling, or needing emergency care for dehydration. Older adults may not feel as thirsty and may have less ability to recover. So, it’s important to watch hydration, electrolytes, blood pressure, and kidney function, especially in the first months of treatment and after increasing the dose.

3) Muscle and frailty: losing weight does not always mean better health.

The headline benefits of GLP‑1s often focus on pounds lost. But the body doesn’t lose only fat. Lean mass (including muscle) can drop, too. This matters in older adults because age‑related muscle loss (sarcopenia) is already common — and it’s tightly linked to frailty, falls, and loss of independence.

A 2025 mini-review on older adults warns that starting and stopping GLP-1s repeatedly can change body composition, sometimes leading to ‘sarcopenic obesity’ — having too much fat and too little muscle. The authors are not saying to avoid GLP-1s, but to remember that weight loss does not always mean better health for older people.

More pointedly, a 24‑month retrospective cohort study in older adults with type 2 diabetes reported that semaglutide use was associated with muscle loss and functional decline, particularly at higher doses and in patients who already had sarcopenia. The authors emphasize individualized risk–benefit assessment and the need for monitoring and intervention.

If you’re reading this as an older adult, it may help to translate the research into plain questions to bring to your next appointment: “If I lose weight, how will we protect my muscles?” “How will we check whether I’m getting weaker?” “What would make us stop or change course?” An older adult who becomes “smaller but weaker” has not gained health — only risk.

4) Other complications: gallbladder, pancreas, vision, and low blood sugar

Gallbladder and bile duct problems can be an unexpected issue. Losing weight already increases the risk of gallstones, and GLP-1s seem to increase it even further. A large review found that using GLP-1 drugs increases the chance of gallbladder or bile duct disease, especially at higher doses, for longer periods, or when used for weight loss.

For older adults, this might present as sudden pain in the upper right side of the belly, nausea, fever, or pain spreading to the back or shoulder. These symptoms should be checked by a physician right away.

GLP-1 drug labels also warn about the risk of sudden pancreatitis and say to get medical help for severe, ongoing belly pain. The overall risk is low, but older adults may have additional risk factors, such as gallstones or high triglycerides. Severe belly pain in later life should always be checked quickly.

Then there’s the risk of blood sugar dropping too low. GLP‑1s don’t usually cause hypoglycemia by themselves, but the risk rises when combined with insulin or sulfonylureas. Semaglutide labeling warns that concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia and may require dose reductions of those agents.

In older adults, hypoglycemia can be particularly dangerous: it can cause falls, confusion, fainting, and cardiac stress. It’s also easier to miss, because symptoms may look like “just being tired” or “a little off today,” especially in someone who already has memory or balance problems.

Eyes and vision deserve special attention. Semaglutide labeling includes a warning about diabetic retinopathy complications and recommends monitoring patients with a history of retinopathy. Beyond labeling, post‑marketing safety monitoring continues to explore visual signals.

A 2025 analysis of FDA adverse event reporting data found a potentially elevated risk of vision‑impairment reports with semaglutide use compared with some other diabetes and weight‑loss medications, and it called for vigilant surveillance and further research. That doesn’t prove the drug causes vision loss in an individual patient, but it is enough to justify a cautious posture: new blurring, blind spots, or sudden changes deserve a same‑week medical call, not a “let’s see if it passes.”

5) Surgery and sedation: delayed stomach emptying can cause problems

GLP‑1 medications slow stomach emptying — one reason people feel full sooner. But that same effect can complicate anesthesia and deep sedation if food remains in the stomach despite standard fasting. A 2024 review describes the connection between GLP‑1 medications, delayed gastric emptying (including gastroparesis), and increased risk of aspiration during anesthesia, as well as possible effects on the absorption of other medications.

This issue has become important enough that several medical groups have created guidelines for surgery. The 2024 guidance says many people can continue taking GLP-1s, but doctors should look for higher-risk situations, such as people with stomach problems or other risks of food entering the lungs, and adjust plans as needed.

This is important for older adults because they are more likely to undergo procedures requiring sedation, such as colonoscopies, joint injections, cardiac procedures, dental work, or surgeries. The easiest and most often missed safety step is to tell every physician involved — surgeon, anesthesiologist, endoscopist, dentist — that you are taking a GLP-1 medication and when you last took it. Do not assume it will be clear in your medical chart.

6) A senior‑friendly “yes, with a plan” approach

If you’re an older adult considering a GLP‑1 (or already taking one), a safer approach often looks like “yes, with monitoring.” That means starting with function, not just the scale: tracking energy, steadiness, and strength in everyday life, not only pounds.

It also means treating hydration as a real medical concern. Ongoing nausea, vomiting, or diarrhea is not just part of getting used to the medicine. These symptoms can affect blood pressure and kidney function, especially when changing doses.

Because muscle matters so much in later life, protecting it should be part of the prescription. That can include discussing protein intake, adding a realistic strength plan (even chair‑based work or physical‑therapy guided resistance), and reassessing the medication if weight loss is accompanied by weakness, poor balance, or reduced stamina.

Older adults should also have their medications reviewed with a focus on preventing low blood sugar. If insulin or a sulfonylurea is being used, doses may need to be adjusted as appetite decreases and blood sugar improves.

Finally, it is important to take symptoms seriously. New stomach pain, ongoing vomiting, or sudden vision changes should be checked by a doctor right away. Before any procedure with anesthesia or deep sedation, make sure to tell the medical team about your GLP-1 use — do not assume they already know.

The GLP-1 medications can help some older adults, but there is less room for mistakes. Side effects can quickly lead to dehydration, frailty, falls, or problems during procedures. The safest approach is not just ‘yes’ or ‘no,’ but ‘yes, with a plan’ — one that protects hydration, nutrition, muscle, vision, and safety during medical care.

The post GLP‑1 Medications in Later Life: Why the “Miracle Shot” Needs a Senior‑Specific Safety Lens appeared first on Medika Life.

In later life, weight loss can be a double‑edged sword. A few pounds off the joints can be both helpful and risky. Shedding a few pounds may ease joint pain, but losing weight without meaning to can be a warning sign. Fast weight loss can also lead to muscle loss, which is key to staying independent.

Experts also point out practical issues: injections need good vision, steady hands, and a regular routine. Stomach and bowel side effects can be tougher for seniors, especially if they’re already losing weight without trying. complicate life for older adults — and how to approach them with a “safety first” mindset.

1) Aging changes the risk–benefit math (even when a drug “works”)

Older adults, especially those who are frail or have several health issues, are often left out of clinical trials. This is important because average trial results may not match the real-life experience of a 75-year-old who takes several medications and needs to manage appetite and hydration.

A 2024 debate paper on GLP-1 drugs in older patients, including those with kidney disease, points out that limited trial data and multiple medications make it harder to judge safety and effectiveness for frailer seniors. Clinicians need to make decisions based on each person, not just on averages. In simple terms, the real question is not whether GLP-1s are good or bad, but whether they help this specific older person with their unique health needs.

There’s another subtle issue: in later life, the goal is often less about chasing an ideal weight and more about protecting function—walking safely, rising from a chair, maintaining balance, staying hydrated, and maintaining enough strength to live independently. So for older adults, the most important question isn’t “How much weight will I lose?” It’s “What will this do to my strength, my nutrition, and my ability to stay steady on my feet?”

2) Common side effects can become serious for older adults.

GLP-1s often cause nausea, vomiting, diarrhea, constipation, and less appetite. Younger people may find these symptoms unpleasant but manageable. For older adults, though, these issues can quickly lead to dehydration, dizziness, and falls, especially if they also take blood pressure medicines or diuretics.

Current FDA labeling for semaglutide products highlights this pathway: stomach and bowel side effects can lead to volume depletion, and acute kidney injury has occurred, including in postmarketing reports. The label advises monitoring kidney function when starting or increasing doses in people who develop severe gastrointestinal reactions, and it notes that dehydration has been part of reported kidney injury cases.

This is how many real-life problems start: a few days of not being able to eat or drink much, then feeling lightheaded, falling, or needing emergency care for dehydration. Older adults may not feel as thirsty and may have less ability to recover. So, it’s important to watch hydration, electrolytes, blood pressure, and kidney function, especially in the first months of treatment and after increasing the dose.

3) Muscle and frailty: losing weight does not always mean better health.

The headline benefits of GLP‑1s often focus on pounds lost. But the body doesn’t lose only fat. Lean mass (including muscle) can drop, too. This matters in older adults because age‑related muscle loss (sarcopenia) is already common — and it’s tightly linked to frailty, falls, and loss of independence.

A 2025 mini-review on older adults warns that starting and stopping GLP-1s repeatedly can change body composition, sometimes leading to ‘sarcopenic obesity’ — having too much fat and too little muscle. The authors are not saying to avoid GLP-1s, but to remember that weight loss does not always mean better health for older people.

More pointedly, a 24‑month retrospective cohort study in older adults with type 2 diabetes reported that semaglutide use was associated with muscle loss and functional decline, particularly at higher doses and in patients who already had sarcopenia. The authors emphasize individualized risk–benefit assessment and the need for monitoring and intervention.

If you’re reading this as an older adult, it may help to translate the research into plain questions to bring to your next appointment: “If I lose weight, how will we protect my muscles?” “How will we check whether I’m getting weaker?” “What would make us stop or change course?” An older adult who becomes “smaller but weaker” has not gained health — only risk.

4) Other complications: gallbladder, pancreas, vision, and low blood sugar

Gallbladder and bile duct problems can be an unexpected issue. Losing weight already increases the risk of gallstones, and GLP-1s seem to increase it even further. A large review found that using GLP-1 drugs increases the chance of gallbladder or bile duct disease, especially at higher doses, for longer periods, or when used for weight loss.

For older adults, this might present as sudden pain in the upper right side of the belly, nausea, fever, or pain spreading to the back or shoulder. These symptoms should be checked by a physician right away.

GLP-1 drug labels also warn about the risk of sudden pancreatitis and say to get medical help for severe, ongoing belly pain. The overall risk is low, but older adults may have additional risk factors, such as gallstones or high triglycerides. Severe belly pain in later life should always be checked quickly.

Then there’s the risk of blood sugar dropping too low. GLP‑1s don’t usually cause hypoglycemia by themselves, but the risk rises when combined with insulin or sulfonylureas. Semaglutide labeling warns that concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia and may require dose reductions of those agents.

In older adults, hypoglycemia can be particularly dangerous: it can cause falls, confusion, fainting, and cardiac stress. It’s also easier to miss, because symptoms may look like “just being tired” or “a little off today,” especially in someone who already has memory or balance problems.

Eyes and vision deserve special attention. Semaglutide labeling includes a warning about diabetic retinopathy complications and recommends monitoring patients with a history of retinopathy. Beyond labeling, post‑marketing safety monitoring continues to explore visual signals.

A 2025 analysis of FDA adverse event reporting data found a potentially elevated risk of vision‑impairment reports with semaglutide use compared with some other diabetes and weight‑loss medications, and it called for vigilant surveillance and further research. That doesn’t prove the drug causes vision loss in an individual patient, but it is enough to justify a cautious posture: new blurring, blind spots, or sudden changes deserve a same‑week medical call, not a “let’s see if it passes.”

5) Surgery and sedation: delayed stomach emptying can cause problems

GLP‑1 medications slow stomach emptying — one reason people feel full sooner. But that same effect can complicate anesthesia and deep sedation if food remains in the stomach despite standard fasting. A 2024 review describes the connection between GLP‑1 medications, delayed gastric emptying (including gastroparesis), and increased risk of aspiration during anesthesia, as well as possible effects on the absorption of other medications.

This issue has become important enough that several medical groups have created guidelines for surgery. The 2024 guidance says many people can continue taking GLP-1s, but doctors should look for higher-risk situations, such as people with stomach problems or other risks of food entering the lungs, and adjust plans as needed.

This is important for older adults because they are more likely to undergo procedures requiring sedation, such as colonoscopies, joint injections, cardiac procedures, dental work, or surgeries. The easiest and most often missed safety step is to tell every physician involved — surgeon, anesthesiologist, endoscopist, dentist — that you are taking a GLP-1 medication and when you last took it. Do not assume it will be clear in your medical chart.

6) A senior‑friendly “yes, with a plan” approach

If you’re an older adult considering a GLP‑1 (or already taking one), a safer approach often looks like “yes, with monitoring.” That means starting with function, not just the scale: tracking energy, steadiness, and strength in everyday life, not only pounds.

It also means treating hydration as a real medical concern. Ongoing nausea, vomiting, or diarrhea is not just part of getting used to the medicine. These symptoms can affect blood pressure and kidney function, especially when changing doses.

Because muscle matters so much in later life, protecting it should be part of the prescription. That can include discussing protein intake, adding a realistic strength plan (even chair‑based work or physical‑therapy guided resistance), and reassessing the medication if weight loss is accompanied by weakness, poor balance, or reduced stamina.

Older adults should also have their medications reviewed with a focus on preventing low blood sugar. If insulin or a sulfonylurea is being used, doses may need to be adjusted as appetite decreases and blood sugar improves.

Finally, it is important to take symptoms seriously. New stomach pain, ongoing vomiting, or sudden vision changes should be checked by a doctor right away. Before any procedure with anesthesia or deep sedation, make sure to tell the medical team about your GLP-1 use — do not assume they already know.

The GLP-1 medications can help some older adults, but there is less room for mistakes. Side effects can quickly lead to dehydration, frailty, falls, or problems during procedures. The safest approach is not just ‘yes’ or ‘no,’ but ‘yes, with a plan’ — one that protects hydration, nutrition, muscle, vision, and safety during medical care.

The post GLP‑1 Medications in Later Life: Why the “Miracle Shot” Needs a Senior‑Specific Safety Lens appeared first on Medika Life.

If you’re an adult in the U.S., you can expect to gain 10 to 25 pounds between your 20s and your 40s. Starting between ages 30 and 40, you may find losing weight and exercising more challenging. The exercise you do may not have the same effect as before. It’s not necessarily a sign that something is wrong. This weight gain in middle age—known as “middle-age spread”—is a natural consequence of aging.

“Your metabolism tends to slow down as you get older,” says NIH’s Dr. Rafael de Cabo, an expert on aging. “But your appetite and your food intake do not. So, you have a steady increase of body weight with age.”

Much of the weight gain comes in the form of fat tissue. The distribution of fat in your body also shifts. There’s less under your skin and more around your internal organs. Meanwhile, you start to lose lean muscle with age. Many people also become less active as they age, especially if they have a job that involves a lot of sitting. This can lead to further fat gain and muscle loss.

Those extra pounds have consequences beyond your clothes not fitting. The risk of many chronic diseases, such as diabetes, heart disease, and neurodegenerative diseases, goes up with age. Excess weight can further heighten these risks.

Fortunately, you can take steps to maintain a healthy weight as you age. Your diet can play a key role. Having a slower metabolism means you’ll need fewer calories. But you also want to make sure you still get all the nutrients your body needs. Get tips on healthy eating as you age.

De Cabo studies the effects of dietary changes on health and longevity. One example is intermittent fasting, in which meals are interspersed with long fasting periods. For example, you might limit eating to only eight hours per day. Studies suggest intermittent fasting may help some people to eat less and keep weight off. But De Cabo and others have been finding that it might also have benefits for your metabolism.

His work has shown that mice live longer and stay healthier when they go for long periods between meals. This was true even if they were eating the same amounts and types of foods as mice that ate whenever they wanted. Other studies have also suggested that periods of fasting may bring benefits beyond weight loss.

Physical activity is important for combating the changes that come with aging, too.

“The key is to maintain an active lifestyle,” de Cabo says. “Try to incorporate daily walks or daily visits to the gym. If you have an office job, get a standup desk, so you spend a few hours a day standing instead of sitting. Small doses of exercise throughout the day will help tremendously.”

Visit: https://newsinhealth.nih.gov/2024/10/stopping-middle-age-spread for more information.

The post Stopping Middle-Age Spread appeared first on Medika Life.

I was standing in my kitchen at 1:07 a.m., the only illumination a cold rectangle from the refrigerator.

It felt like a reversed Caravaggio scene. Darkness everywhere, a harsh pool of light on a plate of leftovers.

I was not hungry.

The light wired me awake. It felt like an invitation to eat.

I am a radiation oncologist.

I discuss circadian clocks with patients more often than most in my specialty because I’ve seen, over decades, how sleep, light, food timing, stress, and movement influence recovery, inflammation, and weight.

When you sit in a treatment room for a long enough time, you start to notice patterns.

People who live in bright evenings and dim mornings often struggle with appetite, cravings, and maintaining a healthy body composition.

They are swimming upstream against their biology.

This is the essay I wish someone had handed me ten years ago.

Light is not neutral.

It is a metabolic signal.

And the way we dose it each day can quietly nudge our insulin, our melatonin, our leptin and ghrelin, our brown fat, and even the clocks inside our liver and pancreas.

Let me show you how to use that to your advantage.

The Night I Realized Light Exposure Could Make You Fat.

In the clinic, I began asking a new question: not just how many hours you sleep, but how much light hits your eyes after sunset.

Most patients stared. Then came the stories: three glowing screens, bright LEDs in the bedroom, a dog walk under sodium street lamps.

Late light. Fragmented sleep.

Late eating. Creeping weight.

Our fat cells tell time. So do our mitochondria. So does your gut microbiome.

Light at the wrong time scrambles those clocks. Scrambled clocks change how you store energy.

Your Fat Has a Clock: Circadian Rhythm, Metabolism, and Weight Gain.

Every cell in your body keeps time.

Morning light anchors the master clock in your brain, which in turn syncs the clocks in your organs and fat cells.

Weak morning light and strong evening light throw those clocks out of phase.

The result is a subtle metabolic jet lag that never ends.

Quiet jet lag doesn’t show up on your calendar. It shows up on your scale.

Melatonin, insulin, and the late-night snack

Melatonin is not just a sleep hormone.

It cross-talks with insulin.

When melatonin levels are high, your ability to handle glucose decreases.

That is adaptive if you are asleep.

It is not adaptive if you are scrolling with a bowl of cereal near midnight.

Bright light at night suppresses melatonin, delays sleep, and shifts appetite later.

You wake underslept, with more ghrelin, less leptin, and a stronger drive to eat ultraprocessed food.

Rinse. Repeat.

Want to reset your metabolism?
→ Get my Micro-Habits bundle for daily light protocols, circadian checklists, and the exact scripts I give patients.

Morning light is metabolic medicine.

Ten minutes of unfiltered outdoor light soon after waking can move your circadian clock earlier, deepen your sleep that night, and improve next-day insulin sensitivity.

Morning light is rich in wavelengths your brain needs to set the day. Indoors, even bright-looking rooms are often one or two orders of magnitude dimmer than outside.

Your brain can tell the difference. So can your pancreas.

If you do one thing after reading this, step outside within 30 minutes of waking.

If it is cloudy, go anyway. If it is winter, aim longer. Treat it as you would a prescription.

Darkness is a habit

We talk about sleep hygiene.

We rarely talk about darkness hygiene.

Your retina is exquisitely sensitive to blue light, but even dim bulbs can disrupt your sleep cycle.

Swap bedside LEDs for warm, low-lux bulbs.

Set your phone to grayscale and enable a screen sunset. Cover the power lights with black tape.

Close the fridge quickly. Dim your home two hours before bed until it resembles a Rembrandt painting.

Your metabolism prefers Rembrandt over Times Square.

What I tell patients in the clinic

1. See the morning light early and consistently.
2. Eat most of your calories in the daylight zone.
3. Dim the house two hours before you want to sleep.
4. Stop eating at least two to three hours before going to bed.
5. Keep the bedroom dark, cool, and free of screens.
6. Anchor wake time seven days a week.
7. Move your body in the day, not at midnight.
8. Treat shift work like altitude. You need extra recovery, extra discipline, and a plan.

Micro-habits that fix your light diet

• Lux-before-latte rule: no coffee until you have been outside.
• Two-switch protocol: one button that turns off all bright overheads at 8 p.m., one that turns on warm lamps. Make darkness effortless.
• Yellow-card your phone: night shift mode, grayscale, and a screen curfew you respect.
• Front-load protein: bigger breakfast and lunch, smaller dinner. Your insulin sensitivity is higher earlier.
• Walk after dinner: even ten minutes blunts the glucose spike and helps your clock wind down.
• Bedroom audit: cover LEDs, use blackout curtains, move chargers to the hallway.
• Weekend consistency: Social jet lag is a form of metabolic jet lag. Keep your wake time within 60 minutes of weekdays.

The lab evidence in plain English

Animal models demonstrate that mistimed light exposure leads to weight gain, even without consuming extra calories.

Human studies have linked nighttime light exposure to a higher BMI, poorer sleep, and worse glucose control.

Shift workers have higher risks of obesity, diabetes, and some cancers.

These conditions are not destiny. They are signals you can change.

If you still want numbers

Chronobiology papers repeatedly show that eating the same calories at night causes a higher postprandial glucose and insulin response than eating them in the morning.

Timed light therapy can correct delayed sleep phase and improve metabolic markers.

Dim light at night correlates with higher rates of depression and weight gain.

Again, correlation is not causation, but the mechanisms are biologically sound.

A one-week protocol to test on yourself

Day 1 to 2

• Wake at the same time both days.
• Get 15 minutes of outdoor light within 30 minutes of waking.
• Track meals. Eat 80 percent of calories by 4 p.m.
• Dim the house lights at 8 p.m. Aim for minimal screen time.
• Sleep in full darkness.

Day 3 to 7

• Extend morning light to 20 minutes.
• Add a 10-minute post-dinner walk.
• Keep dinner smallest and earliest.
• Keep wake time strict.
• Note morning hunger and energy. By day 4, many people report fewer nighttime cravings.

How this plays out in the real world

A patient with breast cancer told me she could not lose weight despite “doing everything right.”

She tracked calories, lifted weights, and avoided ultraprocessed foods. She also answered emails at midnight under bright LED downlights and ate a second dinner at 10:30 p.m.

We moved her dinner to 6 p.m., instituted a house-wide dim at 8 p.m., added morning light exposure, and asked her to maintain a stable wake time, even on weekends.

Six weeks later, she had lost six pounds without changing her total calorie intake.

Her sleep improved. Her cravings diminished.

The scale finally listened.

The broader stakes of light exposure and weight gain

We are the first species to flood the night with light and the day with dimness.

We built a 24-hour culture and then wondered why our biology pushed back.

Weight gain is not a character flaw.

It is often a circadian mismatch.

Fix the light. Observe the effects on hunger, sleep depth, glycemic control, and weight.

Final Thoughts

Light is a drug.

Dose it wisely.

Morning heals.

Evening disrupts.

Darkness is a habit, not a switch.

If your weight has been creeping up, remember this: your first diet is not on your plate.

It is in your eyes.

→ Want my full circadian reset, daily checklists, and Micro-Habits plan? Get the Micro-Habits bundle today.

→ Follow me here on Medium for more science-backed, story-driven guides to living longer and better.

Author bio: I am a radiation oncologist who writes daily about longevity, cancer prevention, and the small habits that change health trajectories.

The post The Strange Link Between Light Exposure and Weight Gain appeared first on Medika Life.

Many of us may take multiple medications daily, and we depend on our prescriber’s ability to monitor those that are safe for us and exclude those that may be problematic. Anyone who wishes to be safer may do a bit of their research, and that’s fine. It does not mean you are suspicious; you only wish to ensure there’s no problem.

Hundreds of medications are listed, and it’s almost impossible for anyone to know if a medication could cause one of those rare effects for you. It is, therefore, in your best interest to be vigilant for these effects. In addition to being aware of the side effects, most patients would not know that the number of side effects may increase as the number of people taking the medication increases. Not every side effect manifests immediately, and it may require a significant increase in medication usage for it to show up.

How does a side effect enter the PDR? Usually, during clinical trials where drugs are being tested on patients, the principal investigator (PI) and those involved at the clinical sites will note any side effects that subjects report. Occasionally, an ultra-concerned clinical investigator may turn up a problem that isn’t one.

I recall a woman who developed a rash during clinical trials of a medication. Later, researchers determined that her caregiver had caused the rash by applying skin cream to her. The rash, however, continued to appear as a side effect of the drug. Although the rash wasn’t severe wasn’t related to the medication, it suggested that the researcher was very cautious about their protocol records.

Over the past several years, the discovery and prescribing of weight loss drugs (usually GLP-1) have been noted to have some mild side effects, and several studies have indicated what to expect in terms of side effects. Gut bacterial action causes bad breath (Ozempic breath), but it was easily manageable, provided the healthcare prescriber also examined any dental problems.

The Potential Risks

In another study, semaglutide was associated with a prevalence of nausea (44.10%), vomiting (24.58%), and gastroesophageal reflux disease (GERD) (6.28%) in obese individuals.

However, researchers are now expressing additional concerns about side effects that have emerged after tens of thousands of people have used these medications. How do these drugs work, and what are they noting?

By stimulating the body to create more insulin, these drugs decrease blood sugar levels. They also slow food’s passage through the stomach and lessen the sugar released into the bloodstream. When the digestive process is delayed, patients experience prolonged feelings of fullness, which can reduce their caloric intake and lead to weight loss. The action of the drugs would seem beneficial, especially for those who need to control their blood sugar levels and their weight.

But there was an increased risk, however, of gastrointestinal disorders, hypotension, syncope, arthritic disorders, nephrolithiasis, and interstitial nephritis associated with GLP-1RA use compared to usual care.

Researchers also followed more than 200,000 diabetics taking GLP-1 meds and over 1.7 million diabetics using other medications to decrease blood sugar for around 3.5 years. The study did find that using GLP-1 was not without its hazards. They found these medications were associated with an increased risk of pancreatitis of 146% and an increased risk of arthritis of 11%. But most of the study’s participants were white men in their 60s and 70s with US VA ties. Such a sample would not necessarily provide the most robust results, and future studies need to be much more diverse in the population studied.

The Vanity Factor

Aside from any physical effects, there is also something women especially might be concerned about: Ozempic face. A New York dermatologist came up with this term. It means that losing weight can make your face look older because of the tissue that is being lost. The fact that videos describing it have received millions of views indicates the extent of concern.

But when it comes to treating type 2 diabetes, the GLP-1 RA family provides positive benefits. In addition to a favorable impact on weight and a low risk of hypoglycemia, all medicines in the class have shown substantial reductions in A1C.

Despite some noted adverse side effects, the medications have proven beneficial to a significant number of users. However, as with everything, the benefits and risks must be weighed carefully, and Ozempic face should not be a negative when considering questions of health.

The post Skinnier, Sicker? Weight-Loss Meds Raise Concerns appeared first on Medika Life.

However, it was only recently that I began targeting something deeper.

Something upstream.

Something ancient.

Inflammation.

Not the helpful kind you get after a cut or cold. That kind heals.

I’m talking about chronic inflammation — the kind that lingers quietly, damaging your blood vessels, brain, joints, and organs like a slow, internal wildfire.

Over time, I’ve come to believe that chronic inflammation is the common thread behind most chronic diseases. The evidence keeps stacking up.

The Number That Predicts How Fast You’re Aging

Most doctors ignore it. I don’t.

medium.com

The Hidden Fire Behind Disease

Dementia? Check.

Type 2 diabetes? Check.

Heart attacks. Strokes. Obesity. Cancer?

Check, check, check.

We call these conditions separate diagnoses.

But I’ve come to see them as symptoms of a deeper cause: the body’s immune system stuck in the “on” position.

Scientists have even coined a term: inflammaging — the chronic, low-grade inflammation that accelerates aging and shortens lifespan.

That realization changed the way I live.

6 Ways I’m Extinguishing the Fire

I don’t believe in silver bullets. But I do believe in stacking small daily wins. Here’s how I’m pushing back against chronic inflammation:

1. Sleep Like It’s Medicine

Sleep isn’t optional. It’s therapeutic.
Insufficient sleep increases inflammatory markers, such as C-reactive protein. But quality sleep can lower them, especially when it becomes a consistent, protected ritual.

I now aim for 7.5–8 hours per night, without apology. I treat it like an appointment; I don’t cancel.

2. Move Daily, Not Occasionally

Exercise cools inflammation, especially the aerobic kind.
Walking. Cycling. Swimming. Even light strength training. They all lower pro-inflammatory cytokines and boost your cellular resilience.
And yes, I consider walking to be medicine.

3. Eat Food That Fights for You

I’ve shifted toward a Mediterranean-style diet, which includes olive oil, vegetables, nuts, berries, and fatty fish.
I’ve also added turmeric, green tea, and fiber-rich legumes.
These foods don’t just fuel me. They protect me from the inside out.

4. Avoid the Fire-Starters

Two habits pour gasoline on inflammation:

• Smoking
• Excess alcohol

I’ve never smoked. But I do drink on occasion — and now I limit that to one glass a week, if that. Most of the time, sparkling water does the trick just fine.

5. Stay Lean for the Right Reason

Weight isn’t just cosmetic — it’s biochemical.

Visceral fat (the kind that wraps around your organs) fuels inflammation and increases risk for cancer, dementia, and heart disease.

I stay lean, not for a mirror, but for my mitochondria.

6. Take Oral Health Seriously

Inflamed gums = inflamed body.

I didn’t always take flossing seriously. But the link between periodontal disease and heart disease — even cognitive decline — is real.

Now I treat my toothbrush like a prescription.

We Can’t Stop Time — But We Can Stop the Fire

Aging is inevitable.

But how do we age?

That’s far more flexible than most people realize.

If you want more energy, sharper cognition, and a lower risk of disease, start by cooling the flame of inflammation.

It’s not glamorous. But it works.

Final Thoughts

I used to think aging was just a number. Now I think it’s a pattern.

A pattern of how we sleep. How do we move? How do we eat?

And how we treat the quiet signals our body sends us — before they become sirens.

You don’t need a prescription to start.

You just need to start.

If you’re interested in aging better, you might also enjoy This One Lab Result Predicts How Long You’ll Live.

Ready to fight inflammation? Download my free ebook here.
📘 Debunked: 7 Health Myths That Quietly Hurt You
You’ll learn the truth about common habits that silently fuel inflammation, disease, and aging — and how to reverse them.

Author bio:
Michael Hunter, MD, is a cancer doctor, writer, and wellness advocate who believes the best medicine often starts outside the hospital walls.

The post How Chronic Inflammation Accelerates Aging — And 6 Ways to Slow It Down appeared first on Medika Life.

A new independent analysis conducted by actuarial firm Milliman reveals that FlyteHealth’s AI-enabled Comprehensive Obesity Care program, piloted in partnership with the State of Connecticut, yielded both high medication adherence and meaningful short-term cost avoidance within its first year.

A Real-World Test: Public Sector, Private Innovation

Faced with surging costs tied to GLP-1 coverage since 2020, Connecticut’s self-insured employee health plan took a bold step in 2023 by launching a pilot with FlyteHealth to better manage obesity treatment for eligible employees and retirees. The results: a projected $1.2 million in pharmaceutical cost avoidance and an 86% adherence rate among new GLP-1 users—figures that far surpass national benchmarks.

In typical commercial settings, just 32% of patients remain on GLP-1 therapy after one year. Worse, only 27% follow their prescribed dosing schedules. These statistics often lead payers to pull back on coverage. But FlyteHealth’s personalized, tech-enabled approach may offer a path forward that makes medical and fiscal sense.

Clinical Expertise Meets AI-Driven Personalization

FlyteHealth’s model blends decades of clinical experience with data intelligence. The care program is rooted in the methodology of obesity medicine expert Dr. Louis Aronne and powered by a patent-pending AI engine that tailors care plans based on individual biometric and behavioral data.

Patients receive virtual care from a multidisciplinary team—physicians, nurse practitioners, and dietitians—alongside medication management, lifestyle coaching, and digital support via wearables and connected devices.

The program’s precision prescribing approach uses BMI-based triage to match patients with the most appropriate treatments, reserving higher-cost medications for those with more severe obesity.

State Leaders Applaud Value-Driven Innovation

“This partnership with FlyteHealth is a clear example of how forward thinking, evidence-based innovation can improve people’s lives while also protecting taxpayer dollars,” said Connecticut State Comptroller Sean Scanlon. “The results show we can deliver high-quality care that’s both clinically effective and fiscally responsible.”

Cheryl Pegus, MD, MPH, FlyteHealth’s executive board chair, echoed that sentiment: “Employers and payers are rightly concerned about costs and access. FlyteHealth is committed to supporting those goals with proven, cost-effective solutions.”

Beyond Cost: Patient Outcomes and Long-Term Potential

While the Milliman study focused solely on pharmaceutical spending, FlyteHealth reports additional health improvements among participants, including:

• A 7.2% reduction in elevated HbA1c
• A 9.4% drop in blood glucose levels
• 13%–16% average weight loss over 12 months

The clinical team also addressed comorbidities such as sleep apnea, steatohepatitis, and cardiovascular disease—highlighting the comprehensive nature of the program.

FlyteHealth CEO Sloan Saunders emphasized that these results demonstrate more than momentary success: “Milliman’s independent analysis validates our model’s ability to achieve patient adherence, optimize resource use, and create meaningful savings. But this is just the start—we’re focused on long-term health and economic impacts.”

Looking Ahead

FlyteHealth plans to evaluate broader medical cost offsets and total cost-of-care reductions in future studies. As demand grows for solutions that bridge innovation with fiscal responsibility, the Connecticut pilot could serve as a national model for scalable, AI-informed obesity and cardiometabolic care.

To access the full Milliman report or learn more, visit www.flytehealth.com.

The post AI-Powered Obesity Care: FlyteHealth Delivers Big Wins for Connecticut’s Public Employees appeared first on Medika Life.

Q&A

Gil Bashe: You called Converge\OIST the “very first gathering.” Why did Okinawa feel like the right birthplace?

Yasushi Yamamoto: Yes, this is the very first gathering, and we named it Converge\OIST because I’m a big fan of ‘OIST’—the context of the birth, this location, these people. It was the right place and people, a great gathering, and a pleasure to meet old friends in such a beautiful, inspiring place.

Gil Bashe: Your career bridges Tokyo boardrooms and Jerusalem start-ups. Where did your obsession with “convergence” begin?

Yasushi Yamamoto: Innovation cannot be done in an isolated form; it should be done in collaboration with various fields. Professionals with beautiful résumés in Tokyo surround me, but many lack a broader vision. They are so good at something particular, yet it’s a pity they’re busy in silos. I saw the lack of collaboration and started my business, raising money from Japanese corporations for Israeli start-ups. That contrast—dinosaurs with big systems but little ‘challenging spirit’ versus entrepreneurs who ‘run and fix’—motivated me to build synergy between powerful pieces.

Gil Bashe: Modern medicine seems to multiply silos every year. How do you see convergence breaking that pattern?

Yasushi Yamamoto: Medicine has become hyper-specialized. We have gastroenterologists who only look at the upper esophagus or the colon, cardiologists in electrophysiology, and neurologists focused on one nerve pathway. They perfect an art, but they have blinders. Convergence is breaking down those walls.

Gil Bashe: Inviting violinists and AI ethicists to the same podium can feel radical. How did people react when you pitched this mix?

Yasushi Yamamoto: People would never believe me if I hadn’t done serious work in the previous decade. Thanks to that track record, we built trust. Gathering in Okinawa sounded out of context for many professionals, but it wasn’t curiosity but trust that made them come.

Gil Bashe: Every July, you disappear into Kyoto’s 1,200-year-old Gion festival to play the traditional Japanese flute. What does a month of music teach a CEO?

Yasushi Yamamoto: Back home, I’m participating and serving. When I set up my company, I realized it would never be greater than this festival. The experience makes me humble. I received a baton from previous generations and must pass it on to the next. After that month, I ask, ‘Two generations later, how will young people judge the work I’m doing now?’

Gil Bashe: You’ve spoken of building on three “wheels”: science, art, and philosophy. Where is Corundum on that journey?

Yasushi Yamamoto: We started in hardcore science and investment, then gradually expanded to art—like Leonardo da Vinci, artist and scientist in one person. In the coming three to five years, I will put the vehicle of philosophy on top. Combining great minds and spirit, we can create something AI alone cannot deliver.

Gil Bashe: What tangible outcomes do you want from Converge?

Yasushi Yamamoto: First, I want to support OIST, an institution I love. We held the first event there; followed by South by Southwest London. I want more gatherings in multiple locations, bringing talented people with good hearts.

Gil Bashe: You’ve set up subsidiaries for neuroscience, virtual mixed human-data AI, and the microbiome. Why those intersections?

Yasushi Yamamoto: Think of the gut–brain axis. Discovery comes from interaction: AI power, system biology, and the microbiome. Add the element of art to inspire other curious, intelligent people, and the community expands.

Gil Bashe: Food as medicine used to be folk wisdom; you’re turning it into data science. How?

Yasushi Yamamoto: We invested in a project from the Weizmann Institute—the deepest phenotype cohort, hundreds of people over 20 years with genes, metabolites, behavior, nutrition. We link ancient wisdom to ultra-modern science by layering AI on that dataset. We are converging the past, the future, and current ways of life.

Gil Bashe: Philosophy sounds noble, but ventures need cash. How do you square capital with conscience?

Yasushi Yamamoto: I strongly believe in setting vision on a solid philosophical idea, but also in the power of capital. Our job is to propose a hypothesis, bring capital, deploy people, and prove the hypothesis with action. So, we’re raising our next venture fund while creating the Corundum Convergence Institute, a U.S. 501(c)(3), as an alternative financing model to advance science.

CLOSING THOUGHTS

Yamamoto-san reframes the entrepreneur’s impossible triangle—mission, money, and meaning—into an orchestral score. Science provides the bass line, art supplies melody, philosophy sets tempo, and well-deployed capital funds the concert hall. As Converge expands from Okinawa to London and beyond, its founder is betting that harmony, not hierarchy, will unlock the next era of precision health.

The takeaway is disarmingly simple for the rest of us: when great minds tune their instruments to work in harmony, the walls separating our disciplines start to fall—and patients everywhere will hear the music of life-sustaining innovation.

According to Gil Granot Mayer, Executive Vice President, Technology Development & Innovation at OIST:

“In just two days, we managed to connect people from different disciplines and geographies, immersing them in the OIST spirit and Okinawa’s culture. From understanding the value of the long tail to different approaches to improving life through the Human Phenotype Project, or the understanding of a new aging mechanism associated with cell membrane damage. I hope that these new connections and cutting-edge talks will spark new collaborations and great results.”

The post Blending Renaissance Thinking and Collaborative Power to Address Global Health Challenges appeared first on Medika Life.

The FemTech Foundation—and Fault Lines

In 2015, fewer than 300 ventures focused on women’s health existed. That number has tripled to 942, according to the Galen Growth HealthTech Alpha™ platform. These ventures now span the female health continuum—gynecology, menopause, oncology, cardiovascular disease, mental health and beyond.

Yet the investment tide has not fully turned in FemTech’s favor. While partnerships have risen 15.3-fold during the past decade, capital deployment has grown only 1.4 times. Compare that to the 2.6x expansion of digital health investments. In 2024, FemTech secured $2.2 billion in funding, a sliver of the $26 billion digital-health pie.

This disparity isn’t due to a lack of innovation—quite the opposite. The problem is systemic: funding gaps, policy voids, and clinical blind spots that overlook the $360 billion “ghost market” of women’s health. That phrase— “ghost market”—is the report’s haunting term for the opportunities left untouched by current investors and providers alike.

From Fertility to Full Spectrum

One of the report’s most critical takeaways is how much the FemTech category is maturing. Fertility tracking and pregnancy apps put the field on the map. But FemTech today is far more.  It recognizes the vast need for medicine to engage with women’s unique health needs, long unaddressed.

The Galen Growth data shows that while gynecology and oncology account for more than half of all FemTech ventures, menopause, chronic pain, autoimmune conditions, cardiovascular disease and mental health are surging into the investment and innovation spotlight. These are not “niche” categories—they represent common, often underdiagnosed or misdiagnosed conditions that disproportionately affect women and impair their quality of life.

This expansion reflects a growing recognition that women’s health is not a subset—it’s a central pillar of public health. As de Salaberry writes in a soon-to-appear Health Tech World byline: “To be transformative, FemTech must address the entirety of the women’s health continuum, including those therapeutic areas that are not traditionally branded as female-specific but affect women in distinct ways.”

Twice the Clinical Evidence—But Still Under Scrutiny

Perhaps the report’s most sobering—and telling—data point is that FemTech ventures generate nearly twice the volume of clinical trials, peer-reviewed research, and regulatory filings as their digital health peers. Twice. That’s not due to past scientific rigor; these companies are held to a higher standard. Founders and advocates must go the extra mile to validate the clinical value of their solutions.

Despite this, systemic barriers remain. The report shows 71 percent of early-stage FemTech ventures struggle to raise a Series A round. Funding the “middle”—those post-seed but pre-scaleup companies—is an urgent priority. Without it, too many promising solutions will stall before reaching the women who need them.

Let’s be clear: this isn’t just about meeting investor milestones. It’s about delivering equity in care. Cardiovascular disease is the leading cause of death among women, yet it remains underrepresented in FemTech portfolios. Alzheimer’s and autoimmune conditions disproportionately affect women, yet receive comparatively little innovation focus.

Those are not oversight gaps. They are deep, systemic failures – disparities in our health innovation system.

From Direct-to-Consumer to Deep Health Integration

Another significant signal of maturity is the shift away from pure direct-to-consumer (DTC) models. In 2024, 42 percent of FemTech partnerships involved health systems, up from just 10 percent in 2020. That’s a tectonic shift from point solutions to systemic integration.

As de Salaberry puts it, “DTC strategies alone cannot reach underserved populations or secure the reimbursement pathways necessary for scale.” Systemic integration—through payers, providers, and public institutions—is essential for sustainability and access. FemTech must live where care happens, not just on consumers’ cell phones.

Regionally, the picture is just as telling, with Europe leading in clinical rigor, with 50 percent of FemTech ventures demonstrating proven clinical strength. North America leads in funding ($1.3B), while Asia-Pacific remains a hub of AI-driven diagnostics, even amid a dip in capital investment. These trends point to what’s next: a future driven by localization, clinical excellence and technology convergence.

Forces Shaping the Future of FemTech

The report outlines five key factors shaping the FemTech evolution during the next five years. They’re worth noting for anyone investing, innovating or advocating for equitable care with an eye toward return on investment:

• Redefining the Scope: FemTech must look beyond reproductive health to address chronic diseases, aging, and behavioral health.
• Breaking the DTC Mold: Success will be defined by integrated partnerships with employers, insurers, and health systems.
• Balancing Rigor and Agility: Regulatory requirements must support innovation without stifling it.
• Funding the Growth Gap: Series A and B support is critical to help early innovators scale.
• Smart Consolidation: M&A isn’t just about exits—it’s about building category leaders with breadth and credibility.

Infrastructure, Not Hype

The key here is infrastructure. FemTech is not a trend—it’s the scaffolding of women’s health innovation. Investors need to hear that message and invest to make this population health category viable.

With nearly half the global workforce made up of women, the ROI on women’s health is not just moral—it’s macroeconomic. The health ecosystem can no longer afford to treat women’s health as an edge case. It is, in fact, the core of population health.

FemTech’s next chapter will be shaped by evidence, equity and integration. It must also be underpinned by trust from payers, providers, and patients. That trust is earned through data, outcomes and the bold assertion that women’s health is health, full stop. This Galen Growth Report goes a long way to demonstrating the positive outcomes when innovation and investment converge.

As Julien de Salaberry wisely states: “The next generation of Femtech isn’t about visibility—it’s about value, integration, and health systems impact.” That’s not just a forecast—it’s a framework for what’s next.

[Editor’s Note: For a deeper dive into the Galen Growth FemTech 2025 report, visit galengrowth.com. The full report and press release, are available now.]

The post Galen Growth FemTech 2.0 Report: Elevating Women’s Health from Niche to Necessity appeared first on Medika Life.

What’s more, exercise is just not for your muscles and your strength. I’ve written on why muscles are involved in mood and you can go to this article to refresh your memory or read it if you haven’t already.

What recent research benefits those over 70? Undoubtedly, we have a great deal more in terms of input in our muscle maintenance than anyone thought when they considered people over 70. The newest research refutes that myth, providing new insights and amazing changes for this group.

But there are specific periods in our lives when certain changes will begin, and with each phase, there will be almost undiscernible changes. However, there are indications that those above 70, who are at greatest risk for instability, balance, problems, muscle weakness, and even bone fractures, require our attention. Previously, adequate work was not directed at the potential maintenance and retrieval of muscle strength in this group, and that is where new, exciting research is coming to the fore.

What Are the Groups?

Sarcopenia is the medical term for muscle loss, and it is a normal aging process that affects all humans, although the rate of onset and the severity of the condition is different among individuals. This slowdown in muscle mass, strength, and function has implications for the quality of life and dependence of the elderly. Muscle loss occurs at different ages and we need to pay attention to enable people to prevent or at least remediate this to some extent.

20s-30s Age Group

In the young adulthood (20s to 30s) age group, muscle mass is at its peak. This age group is likely to have the best muscle strength and function as most people. The body is well equipped to build up and preserve muscle tissue as long as the muscle is used and fed properly. However, even at this young stage, people with sedentary jobs may already experience some muscle atrophy that does not manifest itself clinically. It sets the stage for future deterioration, so appropriate physical activity and diet during these years are a sound investment into future muscle health.

40s Group

Beginning in the 40s, the person begins to show some changes as mentioned above. The literature reviews indicate that muscle mass starts to decline at about 0.5–1% every year after age 30 and the rate increases a little in the 40s. It is also the time when strength reduction is first noticed especially in muscle fibers which control power and speed.

The quadriceps, hamstrings, and calf muscles may start to weaken, especially in people with low levels of physical activity. Most people in this age bracket feel the fatigue and reduced physical endurance when engaging in physical activities.

50s Group

More specific features of muscle atrophy can be observed in the 50s. The rate of loss is higher, currently ranging between 1–2% every year. At this time, the hormonal changes worsen the muscle regeneration. To women menopause reduces the level of estrogen that accelerates muscle loss. Men also have low levels of testosterone that also worsen the muscle tissue.

The abdominal muscles and the lower back muscles, which are the stabilizers, also weaken a lot. Upper body strength, especially in the chest, shoulders, and arms, decreases at a higher rate than before.

60 Group

In the 60s, the loss of muscle is higher and the following rates are observed: 2–3% per year. The consequences of the changes are seen in the everyday life and the person needs help in performing certain actions. The muscles of the lower limb that include the quadriceps, hamstrings and gluteal muscles also weaken greatly.

Many people in this age group will report having problems with stairs, getting up from a chair, or walking for long distances. The hand grip strength is reduced which in turn affects the fine motor skills and the ability to handle objects. The sense of balance is also affected because muscle weakness and neurological changes in proprioception occur.

Over 70 Group

Muscle loss is at its highest in adults over 70, with annual losses of 3–5% if no schedule for slowing or reversing this loss is introduced. This accelerated decline has a major effect on the quality of life and independence. This age group has distinct muscle weakness with well-defined patterns of muscle involvement that have important functional implications

The quadriceps, hamstrings and gluteal muscles are the extremity muscles that are affected in a greater degree. This weakness is manifested as:

1. Difficulty in rising from sitting position
2. Slow walking
3. High chances of falling,
4. Difficulty in climbing stairs. The ankles are also liable to weaken, and this causes the client to have difficulty with walking and increased chances of falling.

Strengthen these muscle groups by including functional exercises that may involve using body weight, resistance bands, or light weights. Of course, any exercise routine in any age group should always be planned with a certified trainer or someone in a rehabilitation facility specifically to address these needs.

Some of the exercises that can be of great help include; standing from a chair, slow walks, sitting leg raises, and ankle exercises to build strength. Exercises in water are an excellent way to work on these muscles with minimum impact on the joints.

Balance is trained very effectively by standing exercises that reduce the base of support step by step. The tandem stance is particularly effective — this is when one stands with one foot in front of the other, heel to toe, to begin with, leaning on a sturdy chair or counter. In the event that stability improves, the support can be reduced to fingertip touch, then to no support at all.

The single leg stance is another basic exercise; start by holding a chair and lift one foot slightly off the floor for 10–15 seconds and then switch to the other side. This exercise directly strengthens the stabilizing muscles around the hips and ankles that are crucial for the prevention of falls.

Weight shifting exercises are used to develop the dynamic balance. The weight shift is to stand with feet hip width apart and then slowly shift weight from one foot to the other without moving the feet. Clock reaches expand on this by visualizing standing at the centre of a clock face and reaching one foot towards different ‘hours’ whilst remaining balanced. These movements enhance proprioception, which is the sense of where the different parts of the body are in space, and this sense is often reduced as one gets older.

The good news is that even though you have lost muscle strength, there is still the ability to help your muscles, pull back some of that strength and renew your ability to move and continue an active lifestyle. As has been noted by several of the articles, water exercises seems to be one of the best, especially for anyone with arthritic conditions. And, don’t forget that exercise is intimately associated with mood.

The post Strength Beyond Years: How Exercise Redefines Aging appeared first on Medika Life.